In a Pinch: Cefiderocol for CRAB Infections

Sara M. Karaba, Elizabeth B. Hirsch, Emily L. Heil

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. (https://doi.org/ 10.1128/aac.02142-21) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections treated with cefiderocol-containing versus colistin-containing regimens. Patients who received cefiderocol-containing regimens had lower 30-day mortality, though there are several limitations raised here, which make interpretation and applicability difficult.

Original languageEnglish (US)
JournalAntimicrobial agents and chemotherapy
Volume66
Issue number5
DOIs
StatePublished - May 2022

Bibliographical note

Funding Information:
Copyright © 2022 American Society for Microbiology. All Rights Reserved. Address correspondence to Sara M. Karaba, sara.karaba@jhmi.edu. For the article discussed, see https://doi.org/ 10.1128/AAC.02142-21. The authors declare a conflict of interest. E.B.H. has received research funding from Merck and advisory board honoraria from Melinta, MeMed, and Merck. E.L.H. consults for Wolters/ Kluwer (LexiComp). The views expressed in this article do not necessarily reflect the views of the journal or of ASM. Published 11 April 2022

Publisher Copyright:
© 2022 American Society for Microbiology.

Keywords

  • Acinetobacter
  • cefiderocol
  • CRAB

PubMed: MeSH publication types

  • Journal Article
  • Comment

Fingerprint

Dive into the research topics of 'In a Pinch: Cefiderocol for CRAB Infections'. Together they form a unique fingerprint.

Cite this